Substrate
science

Supreme Court Faces Deadline on Mifepristone Mail-Order Case

The Supreme Court is expected to take further action by the end of May 12, 2026 in a case involving mail orders of mifepristone, the abortion medication. A federal appeals court had ruled to stop such mail orders. The outcome could affect FDA regulatory authority over drug dispensing rules.

Stat
1 source·May 11, 10:09 PM(17 days ago)·2m read
Supreme Court Faces Deadline on Mifepristone Mail-Order Casecnbc.com
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

The Supreme Court is expected to take further steps by the end of today in a case concerning mail orders of mifepristone, the abortion medication, after it issued a week-long pause on a federal appeals court decision to halt those orders. The case centers on the FDA's 2023 decision to remove the requirement that mifepristone be dispensed only in person.

States hold authority to regulate abortion, but the FDA regulates drugs. The ruling could influence the agency's broader regulatory power as well as abortion providers and patients.

President Trump has signed off on a plan to dismiss the FDA commissioner, according to multiple reports on May 9, 2026. The commissioner had served in the role for a little over a year. The commissioner was scheduled to give an address at an annual 5K race and run with staff on May 9 but did not appear, two agency sources told STAT. The plans to remove the commissioner could still change.

A study published on May 9, 2026 in JAMA Network Open found that people with premenstrual syndrome or premenstrual dysphoric disorder are more likely to have psychiatric disorders, and vice versa. Researchers examined records from a Swedish registry of more than 3.6 million women between 2001 and 2022.

About 105,000 people had diagnoses of premenstrual disorders. Among them, 48 percent had a previous psychiatric diagnosis, compared with nearly 30 percent of matched controls. In the other direction, 37 percent of those with psychiatric diagnoses later received a premenstrual disorder diagnosis, versus 21 percent of those without.

The associations were strongest for depression and anxiety but were also present for ADHD, bipolar disorder and personality disorders. The researchers matched individuals with premenstrual disorders to their unaffected biological sisters as well as to 10 additional unaffected controls.

Previous studies had suggested links but were smaller with shorter follow-up periods.

Researchers in France and Spain have diagnosed dermatophilosis, a bacterial skin disease usually seen in livestock, in more than 25 men who have sex with men across Europe who reported no known exposure to affected animals. The condition produces a rash and is sometimes known as rain rot.

The cases are reminiscent of the 2022 emergence of mpox among gay men, though this disease has so far been milder. One former CDC HIV prevention leader said the key question is what the pattern means in clinical practice.

A state program will provide 400 diapers to some families upon discharge from the hospital after birth, an amount that covers roughly one month's supply for an average infant. The initiative will begin in the next fiscal year at 65 to 75 hospitals serving low-income patients, which account for a quarter of births in the state. The state becomes the third to offer such a free diaper program.

Key Facts

Supreme Court deadline
End of May 12, 2026 on mifepristone case
FDA 2023 rule
Removed in-person dispensing requirement for mifepristone
Swedish study
3.6 million women, 105,000 with PMD diagnoses
Dermatophilosis cases
More than 25 confirmed in European men who have sex with men
Diaper program
400 diapers per family at 65-75 California hospitals

Story Timeline

4 events
  1. May 9, 2026

    Reports emerge that President Trump signed off on plan to dismiss FDA commissioner.

    1 source@statnews
  2. May 9, 2026

    FDA commissioner does not appear at scheduled 5K race event.

    1 source@statnews
  3. May 9, 2026

    JAMA Network Open publishes study on premenstrual and psychiatric disorders.

    1 source@statnews
  4. May 12, 2026

    Supreme Court expected to take further action on mifepristone mail-order case.

    1 source@statnews

Potential Impact

  1. 01

    Supreme Court decision could alter FDA authority to set national drug dispensing rules.

  2. 02

    California hospitals will distribute free diapers to low-income families beginning next fiscal year.

  3. 03

    A ruling against FDA could restrict access to mailed mifepristone in affected states.

  4. 04

    Clinicians may increase screening for psychiatric conditions in patients with menstrual disorders.

Transparency Panel

Sources cross-referenced1
Confidence score75%
Synthesized bySubstrate AI
Word count485 words
PublishedMay 11, 2026, 10:09 PM
Bias signals removed2 across 2 outlets
Signal Breakdown
Loaded 1Speculative 1

Related Stories

WHO Director Visits Congo as Ebola Outbreak SpreadsNpr
science4 hrs ago

WHO Director Visits Congo as Ebola Outbreak Spreads

The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.

Npr
France 24
2 sources
FDA Panel Recommends XFG Variant for Fall Covid Shotsmedpagetoday.com
science2 hrs agoDeveloping

FDA Panel Recommends XFG Variant for Fall Covid Shots

Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.

Stat
1 source
Benzinga Publishes Article on Biotech Stocks During Pandemic Recoveryfinance.yahoo.com
science6 hrs agoDeveloping

Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery

Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…

Benzinga
1 source